What is SYNAPS Dx?
Operating out of Rockville, Maryland, SYNAPS Dx functions as a specialized medical research and development entity dedicated to the identification and treatment of neurodegenerative disorders. By leveraging advanced diagnostic methodologies, the company occupies a critical niche in the life sciences market, bridging the gap between early-stage laboratory discovery and clinical application. Their focus on high-impact neurological health outcomes aligns with broader industry trends prioritizing precision medicine and early intervention strategies for chronic brain-related pathologies.
How much funding has SYNAPS Dx raised?
SYNAPS Dx has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2021): $10M, investors not publicly disclosed
Key Investors in SYNAPS Dx
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for SYNAPS Dx?
With the recent capital injection, SYNAPS Dx is poised to scale its operational capacity and expand its clinical trial infrastructure. The strategic roadmap likely involves deepening its intellectual property portfolio and enhancing its diagnostic platform to meet the rigorous demands of enterprise-level healthcare integration. As the company transitions through this major funding phase, stakeholders will be monitoring the progression of its lead candidates through regulatory milestones, which will be pivotal in determining the firm's long-term market viability and potential for commercialization in the global neuro-health market.
See full SYNAPS Dx company page
